| 초록 |
A type 1 diabetes mellitus, an autoimmune disease, results from the destruction of the beta cell in the pancreas. Ideally pancreatic islet transplantation is a promising remedy because of its dynamic regulation of blood glucose level of patients. However, transplanted islets are eliminated due to host’s immune responses. It was reported that a high-mobility-group-box 1 protein could play a role in transplanted islet rejection. Here we modified the islet surface with glycyrrhizin-chitosan bioconjugate to modulate the release of HMGB1 protein from islet cells. We confirmed that the glycyrrhizin-chitosan bioconjugate could be stably immobilized to islet surface without any damage. Then xenogenically implanted the glycyrrhizin-conjugated islets could cure the blood glucose levels of the mice within normal range more two weeks without any immunosuppressants. Collectively, we demonstrated the feasibility of glycyrrhizin-chitosan bioconjugate for successful outcome of islet transplantation. |
